Bradley Corr, MD
Gynecologic Oncology · Aurora, CONPI 1255566964
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,488 of the $70,013 with a category attached, or 89.3%. 16 manufacturers reported payments, led by GSK at 37.8% of the total. Among gynecologic oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $921.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$26K
- AstraZeneca$9K
- Merck$9K
- AbbVie$7K
- Eisai Inc.$4K
- Tesaro, Inc.$3K
- plus $12K from 10 others
Across 202 payments — averaging $82,216 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$9.7M
- AbbVie$3.6M
- Merck$872K
- Clovis Oncology, Inc.$870K
- Corcept Therapeutics$444K
- Immunogen, Inc.$408K
- plus $737K from 5 others
What the payments were for
- Consulting fees$62,48889%
- Speaking & faculty fees$2,0003%
- Grants$1,3442%
- Travel & lodging$1,4592%
- Food & beverage$2,6574%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $26,457 |
| AstraZeneca | 8 | $9,063 |
| Merck | 5 | $8,795 |
| AbbVie | 6 | $6,699 |
| Eisai Inc. | 3 | $4,125 |
| Tesaro, Inc. | 7 | $3,274 |
| Gilead | 7 | $3,244 |
| Novocure Inc. | 3 | $2,198 |
| Biontech SE | 2 | $2,160 |
| Daiichi Sankyo Inc. | 1 | $1,938 |
| Immunogen, Inc. | 3 | $1,305 |
| Foundation Medicine, Inc. | 1 | $229 |
| Novocure GmbH | 2 | $210 |
| Seagen Inc. | 1 | $129 |
| Genentech USA, Inc. | 1 | $127 |
| Clovis Oncology, Inc. | 2 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,013 in reported general payments places this provider in the 95th percentile of 28 gynecologic oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 13 | $201,963 |
| Everolimus | 12 | $20,849 |
| Letrozole | 22 | $759 |
| Dexamethasone | 20 | $382 |
| Ondansetron Hcl | 16 | $362 |
| Prochlorperazine Maleate | 14 | $150 |
| Medroxyprogesterone Acetate | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Aurora
- Saketh GuntupalliAurora$39K
- Carolyn LefkowitsAurora$11K
- Kian BehbakhtAurora$10K
- Christine WalshAurora$8K
- Lindsay BrubakerAurora$7K
- Jaime ArrudaAurora$4K
- Jill AlldredgeAurora$4K
- Joseph DemariAurora$1K
- Ashley GreenwoodAurora$475
- Eseohi EhimiagheAurora$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.